Clinicopathological Evaluation of Repeated Courses of Intravesical Bacillus Calmette-Guerin Instillation for Preventing Recurrence of Initially Resistant Superficial Bladder Cancer
- 1 September 1996
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 156 (3), 967-971
- https://doi.org/10.1016/s0022-5347(01)65674-x
Abstract
The efficacy of repeated courses of intravesical bacillus Calmette-Guerin (BCG) for superficial bladder cancer was assessed with particular attention to initially resistant cases. A total of 75 patients with stages Ta to T1b superficial transitional cell bladder carcinoma received 6 weekly instillations of 80 mg. Tokyo strain BCG in 40 ml. saline followed by 6 instillations at monthly intervals. If tumors recurred, another course of treatment was given with surgery. Of 17 patients (22.7 percent) with recurrent tumor at followup periods of up to 84 months 12 received an additional course of BCG instillations according to the same protocol after transurethral resection of bladder tumors, and 10 (83.3 percent) showed no further recurrence with or without additional surgery and BCG therapy after a median followup of 42.9 months. Thus, the overall success rate with this approach was 90.7 percent (68 of 75 patients). Comparison of patients with and without recurrence revealed a significant difference in number of tumors before therapy (p less than 0.05), and a pronounced tendency (p = 0.00507) for recurrence after prior systemic chemotherapy or intravesical instillation. The results suggest that up to 3 courses of repeated intravesical instillation of BCG are effective even for cases that initially did not respond, and that best results may be achieved if no other prior chemotherapy has been attempted.Keywords
This publication has 18 references indexed in Scilit:
- Pulmonary granulomata. A complication of intravesical administration of bacillus calmette-guerin for superficial bladder carcinomaCancer, 1993
- Management of Stage T1 Superficial Bladder Cancer with Intravesical Bacillus Calmette-Guerin TherapyJournal of Urology, 1992
- ABLATIVE AND PROPHYLACTIC EFFECTS OF BCG TOKYO 172 STRAIN FOR INTRAVESICAL TREATMENT IN PATIENTS WITH SUPERFICIAL BLADDER CANCER AND CARCINOMA IN SITU OF THE BLADDERThe Japanese Journal of Urology, 1992
- Fatal Sepsis Following Intravesical Bacillus Calmette-Guerin Administration for Bladder CancerJournal of Urology, 1990
- Long-Term Results of Intravesical Bacillus Calmette-Guerin Therapy for Superficial Bladder CancerJournal of Urology, 1989
- ANALYSES OF THE EFFECTS OF INTRAVESICAL BACILLUS CALMETTE-GUERIN (TOKYO 172 STRAIN) THERAPY FOR SUPERFICIAL BLADDER CANCERThe Japanese Journal of Urology, 1989
- Results of 6 Weekly Intravesical Bacillus Calmette-Guerin Instillations on the Treatment of Superficial Bladder TumorsJournal of Urology, 1988
- Risks and Benefits of Repeated Courses of Intravesical Bacillus Calmette-guerin Therapy for Superficial Bladder CancerJournal of Urology, 1987
- Two Courses of Intravesical Bacillus Calmette-Guerin for Transitional Cell Carcinoma of the BladderJournal of Urology, 1986
- Intracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder TumorsJournal of Urology, 1976